# A Study of TG103 Injection in Overweight or Obesity

> **NCT05299697** · PHASE2 · UNKNOWN · sponsor: **CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.** · enrollment: 195 (estimated)

## Conditions studied

- Overweight or Obesity

## Interventions

- **DRUG:** TG103 15 mg
- **DRUG:** TG103 22.5 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05299697
- **Lead sponsor:** CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-20
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2022-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05299697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05299697, "A Study of TG103 Injection in Overweight or Obesity". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05299697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*